|

Venetoclax Clinical Trials

179 actively recruiting trials across 46 locations

▼ -3 trials since June 2026

Also known as: 6-MP, ABT 199, ABT-0199, ABT-199, ABT-199, +34 more

Pipeline

Early 1: 1Phase 1: 32Phase 2: 86Phase 3: 12Phase 4: 2Phase 1/2: 30Phase 2/3: 6

Top Sponsors

  • M.D. Anderson Cancer Center29
  • National Cancer Institute (NCI)11
  • Institute of Hematology & Blood Diseases Hospital, China11
  • First Affiliated Hospital of Zhejiang University6
  • AbbVie6

Indications

  • Cancer179
  • Acute Myeloid Leukemia65
  • Chronic Lymphocytic Leukemia17
  • Refractory Acute Myeloid Leukemia16
  • Recurrent Acute Myeloid Leukemia13

Other58 trials

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
Phase 3
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Phase 2
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia
Phase 2
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2
A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML
Phase 2
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL
N/A
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
Phase 2/3
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
Phase 2
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
Phase 3
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
Phase 2
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
N/A
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
Phase 2
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Phase 2
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
Phase 3
De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients
Phase 2
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
Phase 2
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
N/A
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
Phase 2
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
N/A
Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML
Phase 2
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Phase 1/2
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Phase 1/2
Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.
Phase 2
MRD-positive AML Clinical Study
N/A
Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML
Phase 2
Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML
Phase 2
Newly-diagnosed Pediatric T-cell ALL Protocol
Phase 2/3
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
N/A
Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia
N/A
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Phase 2
Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients
Phase 2
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Phase 3
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
Phase 4
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
Phase 2
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
Phase 2
Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia
Phase 2
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML
Phase 2
Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms
Phase 2
Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease
Phase 2
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
Phase 4
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Phase 2
Study to Evaluate the Safety and Tolerability of EP0042
Phase 1/2
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
Phase 2/3
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
Phase 2
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
Phase 1
VHAG in Treating R/R T-ALL/LBL
Phase 2
Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Phase 2
Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
Phase 2
Venetoclax Combined With Azactidine in the Treatment of ALAL
Phase 2
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
Phase 2/3
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
Phase 2
Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy
N/A
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
Phase 2
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Phase 1/2
Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Phase 2
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
N/A
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
Phase 2

Houston, Texas28 trials

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

MD Anderson Cancer Center

Phase 1/2
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

MD Anderson Cancer Center

Phase 2
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

MD Anderson Cancer Center

Phase 1
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

M D Anderson Cancer Center

Phase 1/2
A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

MD Anderson Cancer Center

Phase 1
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

MD Anderson Cancer Center

Phase 1/2
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M D Anderson Cancer Center

Phase 1/2
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

M D Anderson Cancer Center

Phase 2
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

M D Anderson Cancer Center

Phase 1/2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M D Anderson Cancer Center

Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

M D Anderson Cancer Center

Phase 2
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

M D Anderson Cancer Center

Phase 1
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

M D Anderson Cancer Center

Phase 1/2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

M D Anderson Cancer Center

Phase 2
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

M D Anderson Cancer Center

Phase 1/2
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

MD Anderson Cancer Center

Phase 2
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

MD Anderson Cancer Center

Phase 2
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

M D Anderson Cancer Center

Phase 2
Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

The University of Texas M. D. Anderson Cancer Center

Phase 1/2
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

M D Anderson Cancer Center

Phase 1/2
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

M D Anderson Cancer Center

Phase 2
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

Texas Children's Cancer and Hematology Center

Early 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

M D Anderson Cancer Center

Phase 1/2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

M D Anderson Cancer Center

Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

M D Anderson Cancer Center

Phase 2/3
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

M D Anderson Cancer Center

Phase 2
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

UT MD Anderson

Phase 1
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M D Anderson Cancer Center

Phase 2

Birmingham, Alabama9 trials

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

University of Alabama at Birmingham

Phase 1
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

University of Alabama at Birmingham Cancer Center

Phase 2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

University of Alabama at Birmingham Cancer Center

Phase 2
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

O'Neal Comprehensive Cancer Center, University of Alabama

Phase 1/2
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

University of Alabama at Birmingham Cancer Center

Phase 3
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Children's Hospital of Alabama

Phase 2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

University of Alabama at Birmingham Cancer Center

Phase 2
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

University of Alabama at Birmingham

Phase 1
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

University of Alabama at Birmingham Cancer Center

Phase 2

Boston, Massachusetts9 trials

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

Brigham and Women's Hospital

Phase 1/2
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Dana Farber Cancer Institute (Data Collection and Specimen Analysis)

Phase 2
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

Beth Israel Deaconess Medical Center

Phase 1
CIML NK Cells With Venetoclax for AML

Brigham and Women's Hospital

Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Dana-Farber Cancer Institute

Phase 1/2
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

Research Site

Phase 2
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

Beth Israel Deaconess Medical Center

Phase 2
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Dana-Farber Cancer Institute

Phase 1/2
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Massachusetts General Hospital Cancer Center

Phase 2

Duarte, California8 trials

8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

City of Hope Medical Center

Phase 1
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

City of Hope Medical Center

Phase 1/2
Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

City of Hope Medical Center

Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

City of Hope

Phase 1
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

City of Hope Medical Center

Phase 2
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

City of Hope Comprehensive Cancer Center

Phase 2
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

City of Hope Medical center

Phase 1/2

Tucson, Arizona4 trials

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Arizona Oncology - Tucson - Rudasill /ID# 267552

Phase 3
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Banner University Medical Center - Tucson

Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Banner University Medical Center - Tucson

Phase 2
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Banner University Medical Center - Tucson

Phase 2

Miami, Florida4 trials

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

University of Miami

Phase 2
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

University of Miami

Phase 2
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

University of Miami

Phase 1
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

University of Miami Miller School of Medicine-Sylvester Cancer Center

Phase 2

Los Angeles, California3 trials

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Keck School of Medicine of USC

Phase 2/3
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

University of California, Los Angeles

Phase 2
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

David Geffen School of Medicine at the University of California at Los Angeles

Phase 1/2

Aurora, Colorado3 trials

Cladribine Venetoclax in Monocytic AML

Universtiy of Colorado Hospital

Phase 2
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

University of Colorado

Phase 2
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

University of Colorado Hospital

Phase 1

Rochester, Minnesota3 trials

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Mayo Clinic Rochester

Phase 1
MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Mayo Clinic in Rochester

Phase 1
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Mayo Clinic in Rochester

Phase 2

Columbus, Ohio3 trials

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 2
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

Ohio State University Comprehensive Cancer Center

Phase 2
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1

Phoenix, Arizona2 trials

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Mayo Clinic - Phoenix

Phase 1
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Phoenix Children's Hospital

Phase 3

Palo Alto, California2 trials

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Stanford Cancer Institute

Phase 3
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Stanford Cancer Institute Palo Alto

Phase 2

San Diego, California2 trials

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Rady Children's Hospital

Phase 2
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Rady Children's Hospital

Phase 1

San Francisco, California2 trials

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

San Francisco VA Medical Center, San Francisco, CA

Phase 2
Venetoclax Basket Trial for High Risk Hematologic Malignancies

University of California San Francisco-Benioff Children's Hospital

Phase 1

Tampa, Florida2 trials

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

Moffitt Cancer Center

Phase 2
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

Moffitt Cancer Center

Phase 2

Chicago, Illinois2 trials

Avo In R/R And Previously Untreated MCL

University of Chicago Medical Center

Phase 1/2
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL

University of Chicago Medicine Comprehensive Cancer Center

Phase 1/2

Basking Ridge, New Jersey2 trials

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)

Phase 2
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Phase 2

Cincinnati, Ohio2 trials

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

University of Cincinnati

Phase 2
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Cincinnati Children's Hospital Medical Center

Phase 1

Cleveland, Ohio2 trials

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

Case Western Reserve University

Phase 1
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center

Phase 1/2

Portland, Oregon2 trials

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

OHSU Knight Cancer Institute

Phase 1
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

OHSU Knight Cancer Institute

Phase 2

Seattle, Washington2 trials

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Gilbert, Arizona1 trial

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Banner MD Anderson Cancer Center

Phase 3

Jonesboro, Arkansas1 trial

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

St Bernards Medical Center

Phase 3

Springdale, Arkansas1 trial

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

Highlands Oncology Group ( Site 5405)

Phase 3

Cerritos, California1 trial

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

The Oncology Institute Clinical Research

Phase 2

Clovis, California1 trial

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

UCSF-Fresno

Phase 2

La Jolla, California1 trial

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Moores Cancer Center at UC San Diego /ID# 230157

Phase 2

Laguna Hills, California1 trial

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Uci Health Laguna Hills

Phase 3

Newport Beach, California1 trial

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Hoag Family Cancer Center

Phase 1/2

Orange, California1 trial

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

UCI Chao Family Comprehensive Cancer Center

Phase 1/2

Sacramento, California1 trial

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

University of California Davis Health (UC Davis Health)

Phase 2

West Hollywood, California1 trial

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Berenson Cancer Center

Phase 2

Denver, Colorado1 trial

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Colorado Blood Cancer Institute

Phase 1

New Haven, Connecticut1 trial

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Yale-New Haven Hospital

Phase 1

Coral Gables, Florida1 trial

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

University of Miami, Lennar Foundation Medical Center

Phase 2

Atlanta, Georgia1 trial

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Emory Winship Cancer Institute

Phase 1/2

Evanston, Illinois1 trial

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Northwestern University

Phase 2

Iowa City, Iowa1 trial

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

University of Iowa Health Care

Phase 1

Scarborough, Maine1 trial

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

New England Cancer Specialists

Phase 2

Baltimore, Maryland1 trial

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Johns Hopkins University

Phase 1/2

Bethesda, Maryland1 trial

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

National Institutes of Health Clinical Center

Phase 1/2

Detroit, Michigan1 trial

A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

Duplicate_Henry Ford Health System /ID# 209090

Phase 1

New York, New York1 trial

Imetelstat Combinations in Relapsed AML

Icahn School of Medicine at Mount Sinai

Phase 1

The Bronx, New York1 trial

FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

Montefiore Medical Center

Phase 1

Memphis, Tennessee1 trial

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Baptist Health Care Corporation

Phase 1

Milwaukee, Wisconsin1 trial

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Children's Wisconsin

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.